Steven E. Coutre, MD, professor at the Stanford University Medical Center, discusses the importance of molecular profiling in hematologic diseases, including acute lymphoblastic leukemia.
Steven E. Coutre, MD, professor at the Stanford University Medical Center, discusses the importance of molecular profiling in hematologic diseases, including acute lymphoblastic leukemia (ALL).
Understanding the heterogeneity of a hematologic disease is an important part of making treatment decisions for patients. For example, the Philadelphia chromosome can help oncologists decide whether to put their patients with ALL on either dasatinib (Sprycel) or imatinib (Gleevec).
By having a more robust profile of patients, oncologists will have a better understanding of what drugs to give in combination with chemotherapy for the best outcome, Coutre explains.
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More